Comparison of Safety and Efficacy of Berodual® Administered Via the Respimat® Device With That Administered Via the Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3CompletedINTERVENTIONAL

Enrollment

892

Participants

Timeline

Start Date

February 28, 1998

Primary Completion Date

April 30, 1999

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Berodual® Respimat ® high dose

DRUG

Berodual® Respimat ® low dose

DRUG

Berodual® MDI

DRUG

Placebo